Gurbakhash Kaur

@GKaurMD

Multiple Myeloma/CAR-T Specialist at Mount Sinai Hospital | Montefiore & Tufts Alum | #CAR-T #immunotherapy | Views not representative of my employer.

New York City, New York Joined April 2009

1.1K Following 1.5K Followers 5.8K Posts

Latest posts 5

Gurbakhash Kaur @GKaurMD Oct 7

Refer early

Refer early

Refer early

For CAR-T evaluation.

Henry C Fung| MM, lymphoma, leukemia & CART Verified account @HenrychihangFu1 Oct 5

CAR-T is potentially curative for follicular lymphoma and CLL.

In multiple myeloma—where definitive proof remains aspirational—we are inspired enough to pursue cure.

So I must ask my lymphoma colleagues:

You already have a potentially curative treatment in your hands. Why are you not moved? Why are you not inspired?

Why continue cycling patients through one noncurative therapy after another—and refer for CAR-T only when they are cytopenic, infected, exhausted and rapidly progressing?

Do not wait until CAR-T is no longer possible.

Discuss it early. Refer early. Give every eligible patient the opportunity. #FollicularLymphona #CLL #CART #HemeTwitter

View quoted post on X

Gurbakhash Kaur @GKaurMD Oct 1

Those of you who are more certified in Hematology and Oncology or any other specialty at which point did you say I’m going to let go of my IM board certification?

#medtwitter

Gurbakhash Kaur @GKaurMD Sep 24

The @TischCancer @IcahnMountSinai Myeloma DreaMM TeaMM - missing a few at #IMS26

Gurbakhash Kaur @GKaurMD Sep 23

@DrKrinaPatel shining at #IMS26 in making a case for CART at first relaps.
1. Outcomes are better when CART is done earlier
2. Better Tumor Microenvironment and T cell
Health
3. treatment free time, one and done approach

#mmsm

Gurbakhash Kaur @GKaurMD Sep 23

Maintenance is all about Endurance. #mmsm

Mohamad Mohty Verified account @Mohty_EBMT Sep 23

Maintenance is a marathon, not a sprint.
As we extend therapy to deepen and sustain disease control in myeloma, toxicity becomes part of the efficacy equation. ENDURANCE reminds us that indefinite maintenance may increase burdens such as fatigue, diarrhoea and neutropenia, even without an apparent increase in second primary malignancies.
The future of maintenance is not only about how long we can treat, but how long patients can live well on treatment.
@TheIACH @COMyCongress @myelomaMD @VincentRK

View quoted post on X